NYSEArca - Nasdaq Real Time Price USD

iShares Russell 2000 ETF (IWM)

210.84 -5.74 (-2.65%)
As of 9:51 AM EDT. Market Open.
Loading Chart for IWM
DELL
  • Previous Close 216.58
  • Open 208.85
  • Bid 208.52 x 800
  • Ask 208.56 x 800
  • Day's Range 208.42 - 210.91
  • 52 Week Range 161.67 - 228.63
  • Volume 13,865,130
  • Avg. Volume 30,453,496
  • Net Assets 60B
  • NAV 216.81
  • PE Ratio (TTM) 13.44
  • Yield 1.30%
  • YTD Daily Total Return 8.48%
  • Beta (5Y Monthly) 1.06
  • Expense Ratio (net) 0.19%

The fund generally invests at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index (i.e., depositary receipts representing securities of the underlying index) and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents.

iShares

Fund Family

Small Blend

Fund Category

60B

Net Assets

2000-05-22

Inception Date

Performance Overview: IWM

View More

Trailing returns as of 8/1/2024. Category is Small Blend.

YTD Return

IWM
8.48%
Category
2.25%
 

1-Year Return

IWM
11.01%
Category
10.40%
 

3-Year Return

IWM
0.68%
Category
0.88%
 

People Also Watch

Holdings: IWM

View More

Top 10 Holdings (3.42% of Total Assets)

SymbolCompany% Assets
INSM
Insmed Incorporated 0.42%
FTAI
FTAI Aviation Ltd. 0.42%
ANF
Abercrombie & Fitch Co. 0.36%
FN
Fabrinet 0.36%
SFM
Sprouts Farmers Market, Inc. 0.34%
PCVX
Vaxcyte, Inc. 0.33%
AIT
Applied Industrial Technologies, Inc. 0.30%
FLR
Fluor Corporation 0.30%
HQY
HealthEquity, Inc. 0.30%
SPSC
SPS Commerce, Inc. 0.28%

Sector Weightings

SectorIWM
Healthcare   17.19%
Industrials   15.71%
Technology   15.06%
Real Estate   7.15%
Energy   6.40%
Utilities   2.79%

Recent News: IWM

View More

Research Reports: IWM

View More
  • Biogen Earnings: Shares Undervalued as Cost Controls Materialize and New Launches Accelerate

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     
  • McDonald's Set to Increase Investment in Value Positioning as Consumer Spending Slows

    McDonald’s is the largest restaurant owner-operator in the world, with 2023 system sales of $130 billion across nearly than 42,000 stores and 115 markets. McDonald’s pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.

    Rating
    Price Target
     
  • PayPal Earnings: Focus on Profitable Growth Pays Off

    PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 426 million active accounts at the end of 2023. The company also owns Venmo, a person-to-person payment platform.

    Rating
    Price Target
     
  • Alphabet Earnings: Search and Cloud Growth Remain Impressive

    Alphabet is a holding company. Internet media giant Google is a wholly owned subsidiary. Google services account for nearly 90% of Alphabet's revenue, of which more than 85% is from online ads. Other Google services revenue is from sales of apps and content on Google Play and YouTube, as well as sales of hardware such as Chromebooks, the Pixel smartphone, and smart home products, which include Nest and Google Home. Google's cloud computing offerings account for a bit more than 10% of total Alphabet revenue. Alphabet’s moonshot investments are in its other bets segment, where it bets on technology to enhance health (Verily), provide faster internet access (Google Fiber), enable self-driving cars (Waymo), and more.

    Rating
    Price Target
     

Related Tickers